Quæfacta provides a digital solution bringing trusted traceability in healthcare.
We rely on organisational partnerships and future-proof technology, integrate fragmented information sources and provide companies with real-time data, key analytics and business intelligence to streamline operational activities and assist in improving patient lives and treatment outcomes.
The H Project initiative aims to deliver a positive social, economic and health impact for patients receiving medication treatment for TB and HIV disease in developing countries.
Quæfacta will focus on global development goals, regulatory policies and humanitarian initiatives outlined by organisations including; WHO, EU, OECD, Pharmaceutical companies and NGO’s.
Our project proposal intends to provide end-to-end traceability along the pharmaceutical value chain specifically targeting TB and HIV disease, addressing the logistics of medications supply/usage, and the medication verification process for end users.
Traceability is all about reconstructing processes. From an amount of small pieces of information you’ve recorded patiently, a reconciliation system offers you an actual view of what happened on your supply chain.
At Quæfacta, we understand two things:
Our activity is about enabling common grounds for traceability, may they be at a technical level or at a business level. And we rely on blockchains to increase trust at each bit of information you put in the system.
Fragmented processes and complexities across the pharmaceutical supply chain give way to fake medications and falsified information flooding the supply chain. The consequences of these complicated processes gives rise to illicit activity, fraud and abuse which may cause serious harm and fatal outcomes.
At Quæfacta, we focus on bringing traceability and security to global pharmaceutical supply chains. We achieve this by providing companies, partners and stakeholders with key analytics, real time notifications and reporting. This provides our clients traceability and visibility on stock movements, information to improve clinical decision making, as well as providing key information for continuous monitoring and improvement.
Quæfeacta SAS is being created at the moment.
The company is located in Paris, France.